Evidence map›Paper›PMID 34409386›Full record

ArticleJAAD international2021

Comparison of community pathologists with expert dermatopathologists evaluating Breslow thickness and histopathologic subtype in a large international population-based study of melanoma.

Joseph Michael Yardman-Frank, Baillie Bronner, Stefano Rosso, Lynn From, Klaus Busam, Pam Groben, Paul Tucker, Anne Cust, Bruce Armstrong, Anne Kricker and 15 more

Abstract read
In one paragraph

Article in JAAD international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Joseph Michael Yardman-FrankUniversity of New Mexico School of Medicine, Albuquerque, New Mexico.
Baillie BronnerUniversity of New Mexico School of Medicine, Albuquerque, New Mexico.
Stefano RossoCPO Piemonte, Turin, Italy.
Lynn FromCancercare Ontario, Toronto, Canada.
Klaus BusamMemorial Sloan Kettering Cancer Center, New York, New York.
Pam GrobenUniversity of North Carolina, Chapel Hill, North Carolina.
Paul TuckerMenzies Centre, Hobart, Tasmania, Australia.
Anne CustSydney University, New South Wales, Australia.
Bruce ArmstrongSydney University, New South Wales, Australia.
Anne KrickerSydney University, New South Wales, Australia.
Loraine MarrettCancercare Ontario, Toronto, Canada.
Hoda Anton-CulverUniversity of California, Irvine, California.
Stephen GruberUniversity of Michigan, Ann Arbor, Michigan.
Rick GallagherBritish Columbia Cancer Research Center, Vancouver, Canada.
Roberto ZanettiCPO Piemonte, Turin, Italy.
Lidia SacchettoCPO Piemonte, Turin, Italy.
Terry DwyerMenzies Centre, Hobart, Tasmania, Australia.
Alison VennMenzies Centre, Hobart, Tasmania, Australia.
Irene OrlowMemorial Sloan Kettering Cancer Center, New York, New York.
Peter KanetskyUniversity of Pennsylvania, Philadelphia.
Li LuoUniversity of New Mexico School of Medicine, Albuquerque, New Mexico.
Nancy ThomasUniversity of North Carolina, Chapel Hill, North Carolina.
Colin BeggMemorial Sloan Kettering Cancer Center, New York, New York.
Marianne BerwickUniversity of New Mexico School of Medicine, Albuquerque, New Mexico.
GEM Study Team

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Sex Differences in Methylome Alterations and Mutational Burden in Early Stage MelanomaP01CA206980 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BERWICK, MARIANNE, THOMAS, NANCY E. · 2017 to 2022
$10.1M
Melanoma RAS/BRAF Mutation:Heterogeneity-Risk-PrognosisR01CA112243 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E. · 2005 to 2014
$5.4M
A MODEL FOR GENETIC SUSCEPTIBILITY: MELANOMAU01CA083180 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 1999 to 2003
$5.2M
Identification of Lethal Melanomas at the Time of DiagnosisR01CA233524 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANTON-CULVER, HODA A, BEGG, COLIN B · 2020 to 2024
$4.5M
Mutational Analysis of Clonality in Multiple Primary MelanomaR03CA125829 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ORLOW, IRENE · 2006 to 2007
$128k
NCI NIH HHS P01 CA206980NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016086NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA112243NCI NIH HHS R01 CA233524NCI NIH HHS R03 CA125829NCI NIH HHS U01 CA083180
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34409386
PMCPMC8362323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.